Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Expands License to Roche IVD Patents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has expanded its license to certain Roche in vitro diagnostic patents, granting the firm rights to manufacture and sell validated kits covered by the Roche patents to the IVD market.

The kits Biosearch intends to sell will include probes, primers, enzymes, and any other essential reagents necessary to amplify and detect diagnostic targets. As a result, the Novato, Calif.-based firm will expand beyond being a provider of oligonucletoide components for molecular diagnostics to being a provider of diagnostic kits.

Last year, Biosearch had licensed a family of patents from Roche Molecular Systems covering uses of the 5' Nuclease process. It followed that up with a license from the US Centers for Disease Control and Prevention for patents covering the 2009 H1N1 and Influenza A Sub-typing signatures.

"With this expanded Roche license, Biosearch is poised to enter the IVD marketplace as a pivotal manufacturer of diagnostic kits," Marc Beal, director of corporate development at Biosearch Technologies, said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.